BRAIN RESEARCH is a premier journal published by Elsevier, specializing in the intricate domains of neuroscience, developmental biology, and molecular biology. Established in 1966, this esteemed publication has become a cornerstone for researchers, professionals, and students dedicated to advancing our understanding of brain function and disorders. With an impressive impact factor and a consistent presence in the Q2 quartiles across key categories—such as Developmental Biology, Neurology, and Neuroscience—it stands out as an essential resource for disseminating innovative research and pioneering insights. The journal's scope encompasses both clinical and fundamental studies, fostering a multidisciplinary approach to the complexities of neural systems. Although it is not an open-access journal, BRAIN RESEARCH provides a vital platform for sharing progressive findings that can inspire future studies and contribute significantly to the evolutionary discourse in neuroscience. Based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, BRAIN RESEARCH continues to shape the landscape of neuroscience research, inviting submissions that explore the latest discoveries and therapeutic strategies.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

Translational Neuroscience, published by DE GRUYTER POLAND SP Z O O, is a leading open-access journal since its inception in 2015, dedicated to the multidisciplinary exploration of neurological research and its clinical applications. With an ISSN of 2081-3856 and an E-ISSN of 2081-6936, the journal serves as a crucial platform for scholars and practitioners to disseminate innovative findings and theoretical advancements in the field of neuroscience. Covering various aspects of general neuroscience, it is ranked in the Q3 quartile for 2023 and positioned at Rank #75 out of 113 in its category, reflecting its growing impact within the scientific community. The journal strives to bridge the gap between laboratory research and clinical practice, fostering collaboration among researchers, clinicians, and educators. The editorial team is committed to maintaining high publication standards that engage the audience with rigorous research while promoting a culture of open science. For those interested in the forefront of neuroscience research, Translational Neuroscience offers an invaluable resource for knowledge and innovation.

Neuropeptides is a prestigious, peer-reviewed journal published by Elsevier, focusing on the critical role of neuropeptides in various biological processes and their implications in cellular and molecular neuroscience, endocrinology, and neurology. With an impact factor reflecting its influence in the field and a diverse audience ranging from researchers to healthcare professionals, the journal serves as an essential platform for the dissemination of groundbreaking research from 1980 to 2024. Adhering to high academic standards, Neuropeptides holds a Q3 ranking in Cellular and Molecular Neuroscience and Endocrine and Autonomic Systems, alongside a solid Q2 ranking in both Endocrinology and Neurology. This positions the journal at the forefront of its disciplines, contributing valuable insights into the understanding of neuropeptide functions in health and disease. By not operating as an Open Access journal, it ensures sustainability in the publishing process while upholding rigorous review standards. Researchers, professionals, and students are encouraged to engage with the findings published in this journal, which plays a vital role in advancing knowledge and fostering collaboration within the neuroscientific community.

IBRO Neuroscience Reports, published by Elsevier, is a pivotal open-access journal dedicated to advancing the field of neuroscience. With its ISSN 2667-2421, the journal serves as a vital platform for researchers, professionals, and students alike, showcasing innovative research and interdisciplinary studies that span various aspects of neuroscience. Since its inception in 2021, and with a planned convergence through 2024, the journal has quickly established itself within the academic community, currently holding a Q3 category ranking in the field of Neuroscience (miscellaneous) and a Scopus rank of #77 among 113 in General Neuroscience, reflecting its ongoing commitment to quality and relevance. The accessibility of research articles ensures that critical findings are widely disseminated, fostering collaboration and dialogue within the neuroscientific community. Researchers and professionals are encouraged to contribute to this dynamic journal, reinforcing its role in shaping the future of neuroscience research.

PSYCHOPHARMACOLOGY is a leading peer-reviewed journal specializing in the field of pharmacology, specifically focusing on the effects of drugs on behavior, cognition, and emotion. Published by Springer, this esteemed journal has established itself as a pivotal resource for researchers and professionals since its inception in 1959, maintaining its relevance and rigor in the ever-evolving landscape of psychopharmacological research. With an impressive impact factor and ranking in the top quartile (Q1) of the Pharmacology category in 2023, it consistently publishes high-quality studies that contribute to both academic inquiry and clinical practice. The journal's scope includes original research, theoretical papers, and reviews, fostering a multidisciplinary dialogue among psychologists, psychiatrists, pharmacologists, and neuroscientists. As the field of psychopharmacology continues to grow, PSYCHOPHARMACOLOGY remains dedicated to disseminating innovative findings, operationalizing complex concepts, and enhancing the understanding of drug mechanisms and their implications for mental health. This commitment to excellence positions PSYCHOPHARMACOLOGY as an indispensable tool for those seeking to advance their knowledge and research in pharmacology.

Eneurobiologia is an esteemed open-access journal published by UNIV VERACRUZANA, INST INVESTIGACIONES & EDUCACION, dedicated to advancing research in the vibrant field of neurobiology. With its launch in 2010, the journal aims to disseminate high-quality, peer-reviewed research articles that explore the complexities of neural systems, neurodevelopment, and neurodegenerative disorders. By providing a platform for both established researchers and emerging scholars, Eneurobiologia fosters interdisciplinary collaboration and knowledge exchange within the scientific community. Its open-access model ensures that valuable findings are accessible to a global audience, promoting the widespread application of neurobiological research. As a crucial resource for students, professionals, and researchers alike, Eneurobiologia plays a pivotal role in shaping the future of neurobiological studies and enhancing our understanding of the brain and nervous system.

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.